Hepatic profile analyses of tipranavir in Phase II and III clinical trials
Jaromir Mikl, Mark S Sulkowski, Yves Benhamou, Douglas Dieterich, Stanislas Pol, Jürgen Rockstroh, Patrick A Robinson, Mithun Ranga, Jerry O Stern, Jaromir Mikl, Mark S Sulkowski, Yves Benhamou, Douglas Dieterich, Stanislas Pol, Jürgen Rockstroh, Patrick A Robinson, Mithun Ranga, Jerry O Stern
Abstract
Background: The risk and course of serum transaminase elevations (TEs) and clinical hepatic serious adverse event (SAE) development in ritonavir-boosted tipranavir (TPV/r) 500/200 mg BID recipients, who also received additional combination antiretroviral treatment agents in clinical trials (TPV/r-based cART), was determined.
Methods: Aggregated transaminase and hepatic SAE data through 96 weeks of TPV/r-based cART from five Phase IIb/III trials were analyzed. Patients were categorized by the presence or absence of underlying liver disease (+LD or -LD). Kaplan-Meier (K-M) probability estimates for time-to-first US National Institutes of Health, Division of AIDS (DAIDS) Grade 3/4 TE and clinical hepatic SAE were determined and clinical actions/outcomes evaluated. Risk factors for DAIDS Grade 3/4 TE were identified through multivariate Cox regression statistical modeling.
Results: Grade 3/4 TEs occurred in 144/1299 (11.1%) patients; 123/144 (85%) of these were asymptomatic; 84% of these patients only temporarily interrupted treatment or continued, with transaminase levels returning to Grade < or = 2. At 96 weeks of study treatment, the incidence of Grade 3/4 TEs was higher among the +LD (16.8%) than among the -LD (10.1%) patients. K-M analysis revealed an incremental risk for developing DAIDS Grade 3/4 TEs; risk was greatest through 24 weeks (6.1%), and decreasing thereafter (>24-48 weeks: 3.4%, >48 weeks-72 weeks: 2.0%, >72-96 weeks: 2.2%), and higher in +LD than -LD patients at each 24-week interval. Treatment with TPV/r, co-infection with hepatitis B and/or C, DAIDS grade >1 TE and CD4+ > 200 cells/mm3 at baseline were found to be independent risk factors for development of DAIDS Grade 3/4 TE; the hazard ratios (HR) were 2.8, 2.0, 2.1 and 1.5, respectively. Four of the 144 (2.7%) patients with Grade 3/4 TEs developed hepatic SAEs; overall, 14/1299 (1.1%) patients had hepatic SAEs including six with hepatic failure (0.5%). The K-M risk of developing hepatic SAEs through 96 weeks was 1.4%; highest risk was observed during the first 24 weeks and decreased thereafter; the risk was similar between +LD and -LD patients for the first 24 weeks (0.6% and 0.5%, respectively) and was higher for +LD patients, thereafter.
Conclusion: Through 96 weeks of TPV/r-based cART, DAIDS Grade 3/4 TEs and hepatic SAEs occurred in approximately 11% and 1% of TPV/r patients, respectively; most (84%) had no significant clinical implications and were managed without permanent treatment discontinuation. Among the 14 patients with hepatic SAE, 6 experienced hepatic failure (0.5%); these patients had profound immunosuppression and the rate appears higher among hepatitis co-infected patients. The overall probability of experiencing a hepatic SAE in this patient cohort was 1.4% through 96 weeks of treatment. Independent risk factors for DAIDS Grade 3/4 TEs include TPV/r treatment, co-infection with hepatitis B and/or C, DAIDS grade >1 TE and CD4+ > 200 cells/mm3 at baseline.
Trial registration: US-NIH Trial registration number: NCT00144170.
Figures
References
- Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet. 1998;9142:1725–1730. doi: 10.1016/S0140-6736(98)03201-2.
- Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–860. doi: 10.1056/NEJM199803263381301.
- Vittinghoff E, Scheer S, O'Malley P, Colfax G, Holmberg SD, Buchbinder SP. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis. 1999;179(3):717–720. doi: 10.1086/314623.
- Drake JW. Rates of spontaneous mutation among RNA viruses. Proc Natl Acad Sci USA. 1993;90:4171–4175. doi: 10.1073/pnas.90.9.4171.
- Cooper D, Hall D, Jayaweera D. Baseline phenotypic susceptibility to tipranavir/ritonavir is retained in isolates from patients with multiple protease inhibitor experience (BI 1182.52). [abstract 596] Presented at: 10th Conference on Retroviruses and Opportunistic Infections; Boston. 2003.
- Hicks CB, Cahn P, Cooper DA, Walmsley SL, Katlama C, Clotet B. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet. 2006;368:466–475. doi: 10.1016/S0140-6736(06)69154-X.
- Becker S. Liver Toxicity in Epidemiological Cohorts. Clinical Infectious Diseases. 2004;38:S49–S55. doi: 10.1086/381447.
- Nunez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol. 2006;44:S132–S139. doi: 10.1016/j.jhep.2005.11.027.
- Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS. 2004;18:2277–2284. doi: 10.1097/00002030-200411190-00008.
- Rodriguez-Rosado R, Garcia-Samaniego J, Soriano V. Hepatotoxicity after introduction of highly active antiretroviral therapy. [Letter] AIDS. 1998;12:1256. doi: 10.1097/00002030-199810000-00025.
- Luzuriaga K, McManus M, Mofenson L, Britto P, Graham B, Sullivan JL. A trial of three antiretroviral regimens in HIV-1-infected children. N Engl J Med. 2004;350:2471–2480. doi: 10.1056/NEJMoa032706.
- Crum NF, Riffenburgh RH, Wegner S, Agan BK, Tasker SA, Spooner KM. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr. 2006;41:194–200. doi: 10.1097/01.qai.0000179459.31562.16.
- Soriano V, Garcia-Samaniego J, Rodriguez-Rosado R, Gonzalez J, Pedreira J. Hepatitis C and HIV infection: biological, clinical, and therapeutic implications. J Hepatol. 1999;31(Suppl 1):119–123. doi: 10.1016/S0168-8278(99)80387-0.
- Winnock M, Salmon-Ceron D, Dabis F, Chene G. Interaction between HIV-1 and HCV infections: towards a new entity? J Antimicrob Chemother. 2004;53:936–946. doi: 10.1093/jac/dkh200.
- Schiavini M, Angeli E, Mainini A, Zerbi P, Duca PG, Gubertini G. Risk factors for fibrosis progression in HIV/HCV coinfected patients from a retrospective analysis of liver biopsies in 1985-2002. HIV Medicine. 2006;7:331–337. doi: 10.1111/j.1468-1293.2006.00384.x.
- Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283:74–80. doi: 10.1001/jama.283.1.74.
- Sauleda S, Martorell M, Esteban JI, Tural C, Ruiz I, Puig L. Hepatotoxicity of antiretroviral drugs in HIV HCV patients with congenital coagulopathies followed at an Haemophilia Unit during a decade. Haemophilia. 2006;12:228–236. doi: 10.1111/j.1365-2516.2006.01211.x.
- DAIDS. National Institutes of Health, Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, version 1.0. 2004.
- Sulkowski M, Rockstroh J, Soriana V, Stern J, Mikl J. Clinical course of increased LFTs and hepatic events associated with ritonavir (RTV)-boosted tipranavir (TPV/r) based therapy in the RESIST trials [abstract H-1899] Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco. 2006.
- Torti C, Lapadula G, Casari S, Puoti M, Nelson M, Quiros-Roldan E. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. BMC Infectious Diseases. 2005;5:1–10. doi: 10.1186/1471-2334-5-58.
- Bonfanti P, Landonio S, Ricci E, Martinelli C, Fortuna P, Faggion I. Risk Factors for Hepatotoxicity in Patients Treated With Highly Active Antiretroviral Therapy. [Letter] JAIDS Journal of Acquired Immune Deficiency Syndromes. 2001;27:316–318.
- Becker S. Liver toxicity in epidemiological cohorts. Clin Infect Dis. 2004;38:S49–S55. doi: 10.1086/381447.
- Gisolf EH, Dreezen C, Danner SA, Weel JL, Weverling GJ. Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group. Clin Infect Dis. 2000;31:1234–1239. doi: 10.1086/317449.
- Servin-Abad L, Molina E, Baracco G, Arosemena L, Regev A, Jeffers L. Liver enzymes elevation after HAART in HIV-HCV co-infection. J Viral Hepat. 2005;12:429–434. doi: 10.1111/j.1365-2893.2005.00617.x.
- Gathe JC Jr, Pierone G, Piliero P, Arasteh K, Rubio R, Lalonde RG. Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients. AIDS Res Hum Retroviruses. 2007;23:216–223. doi: 10.1089/aid.2006.0178.
- Leith J, Walmsley S, Katlama C. Pharmacokinetics and safety of tipranavir/ritonavir (TPV/r) alone or in combination with saquinavir (SQV), amprenavir (APV), or lopinavir (LPV): interim analysis of BI1182.51 [abstract 5.1] Presented at: 5th International Workshop on Clinical Pharmacology of HIV Therapy; Rome. 2004.
- Cahn P, Villacian J, Lazzarin A, Katlama C, Grinsztejn B, Arasteh K. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis. 2006;43:1347–1356. doi: 10.1086/508352.
- Gathe J, Cooper DA, Farthing C, Jayaweera D, Norris D, Pierone G Jr. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. Clin Infect Dis. 2006;43:1337–1346. doi: 10.1086/508353.
- Pierone G, Drulak M, Arastéh K. A long-term open-label rollover trial assessing the safety and tolerability of combination tipranavir and ritonavir (TPV/r) use in HIV-1-infected patients [poster WePe6.2C05] Presented at: 3rd International AIDS Conference; Rio de Janeiro. 2005.
- Farthing C, Ward D, Hicks C. Tipranavir/r demonstrates superior and durable treatment response compared with comparator PI/r in highly treatment experienced patients: Week 96 RESIST 1 and 2 results [abstract H-1385] Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco. p. 2006.
- Hicks C, Cahn P, Jelaska A, Drulak M, Vinisko R. Tipranavir/r (TPV/r) maintains long term virological suppression - Week 156 results of RESIST [poster P7.3/25] Presented at: 11th European AIDS Conference; Madrid. 2007.
- Orenstein R, Tsogas N. Looking Beyond Highly Active Antiretroviral Therapy: Drug-Related Hepatotoxicity in Patients with Human Immunodeficiency Virus Infection. Pharmacotherapy. 2002;22:1468–1478. doi: 10.1592/phco.22.16.1468.33702.
- Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 2002;35:182–189. doi: 10.1053/jhep.2002.30319.
- Sulkowski MS. Drug Induced Liver Injury Associated with Antiretroviral Therapy that Includes HIV 1 Protease Inhibitors. Clinical Infectious Diseases. 2004;38:S90–S97. doi: 10.1086/381444.
- den Brinker M, Wit FW, Wertheim-van Dillen PM, Jurriaans S, Weel J, van LR. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS. 2000;14:2895–2902. doi: 10.1097/00002030-200012220-00011.
- John R, Senior M, AASLD-FDA-NIH-PhRMA Hepatotoxicity Steering Group Meeting 2006 Presentations. Adaptation to Liver Injury Tacrine, Isoniazid, Ethanol, Experimental Drugs. 2006.
- Scherpbier HJ, Bekker V, van LF, Jurriaans S, Lange JM, Kuijpers TW. Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort. Pediatrics. 2006;117:e528–e536. doi: 10.1542/peds.2005-1272.
- Kress KD. Antiretroviral-associated Hepatotoxicity. Curr Infect Dis Rep. 2005;7:103–107. doi: 10.1007/s11908-005-0068-z.
- Brau N, Bini EJ, Shahidi A, Aytaman A, Xiao P, Stancic S. Prevalence of hepatitis C and coinfection with HIV among United States veterans in the New York City metropolitan area. Am J Gastroenterol. 2002;97:2071–2078.
- Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34:831–837. doi: 10.1086/339042.
- Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA. 2002;288:199–206. doi: 10.1001/jama.288.2.199.
- Umeh OC, Currier JS. Sex differences in pharmacokinetics and toxicity of antiretroviral therapy. Expert Opin Drug Metab Toxicol. 2006;2:273–283. doi: 10.1517/17425255.2.2.273.
- Guitton E, Montastruc JL, Lapeyre-Mestre M. Influence of HCV or HBV coinfection on adverse drug reactions to antiretroviral drugs in HIV patients. Eur J Clin Pharmacol. 2006;62:243–249. doi: 10.1007/s00228-005-0080-0.
- Wester CW, Okezie OA, Thomas AM, Bussmann H, Moyo S, Muzenda T. Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial. J Acquir Immune Defic Syndr. 2007;46:318–322. doi: 10.1097/QAI.0b013e3181568e3f.
- Mould DR, Zhang X, Nieforth K, Salgo M, Buss N, Patel IH. Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patients. Clin Pharmacol Ther. 2005;77:515–528. doi: 10.1016/j.clpt.2005.02.005.
- Johnson MO, Charlebois E, Morin SF, Catz SL, Goldstein RB, Remien RH. Perceived adverse effects of antiretroviral therapy. J Pain Symptom Manage. 2005;29:193–205. doi: 10.1016/j.jpainsymman.2004.05.005.
Source: PubMed